BRIDGEWAY CAPITAL MANAGEMENT, LLC

Position in DSGN — Design Therapeutics, Inc.

CIK 1107261 HOUSTON, TX

Position in DSGN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$553,280

-$183,050 QoQ

Shares Held

52,000

-33.8% QoQ

Ownership

0.083%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

BRIDGEWAY CAPITAL MANAGEMENT, LLC holds $59,315,164 across 112 Biotechnology names. DSGN ranks #26 (0.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	GLUE	Monte Rosa Therapeutics, Inc.	528,698	$8,697,082
2	PBYI	Puma Biotechnology, Inc.	775,341	$4,954,428
3	EXEL	Exelixis, Inc.	66,100	$2,835,029
4	KROS	Keros Therapeutics, Inc.	195,017	$2,152,987
5	SGMT	Sagimet Biosciences Inc.	299,641	$1,565,624
6	BDTX	Black Diamond Therapeutics, Inc.	723,477	$1,541,006
7	PTCT	Ptc Therapeutics, Inc.	22,000	$1,498,860
8	KYTX	Kyverna Therapeutics, Inc.	149,900	$1,293,637

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$553,280	52,000	-33.8%	Shares	Sole	2026-05-15
2025-12-31	$736,330	78,500	-58.3%	Shares	Sole	2026-02-17
2025-09-30	$1,417,146	188,200	0.0%	Shares	Sole	2025-11-14
2025-06-30	$634,234	188,200	+65.4%	Shares	Sole	2025-08-14
2025-03-31	$439,268	113,800	-11.4%	Shares	Sole	2025-05-15
2024-12-31	$792,228	128,400	-45.5%	Shares	Sole	2025-02-14
2024-09-30	$1,267,528	235,600	0.0%	Shares	Sole	2024-11-14
2024-06-30	$789,260	235,600	+61.5%	Shares	Sole	2024-08-14
2024-03-31	$587,977	145,900	0.0%	Shares	Sole	2024-05-15
2023-12-31	$386,635	145,900	+81.2%	Shares	Sole	2024-02-14
2023-09-30	$189,980	80,500	—	Shares	Sole	2023-11-14
No filing history on record for this holder in this stock.